Effective Fat Burners
The term “fat burner” does not describe a chemical class.
The term “fat burner” does not describe a chemical class. It covers compounds with entirely different molecular targets, levels of evidence and legal status. This article organises them by mechanism, explains what has actually been studied for each group and does not omit the gaps in the data. It contains no dosing or stacking protocols, and most of the compounds discussed are research-grade materials without marketing authorisation.
All substances discussed in this article are research materials and are not intended for human consumption. Descriptions of their activity are based solely on laboratory research and experimental observations, not on clinical testing of the products offered by Pro-Body.
Earlier fat burners: what the clenbuterol case teaches us
It is worth starting with the story that best illustrates why “it works” and “it is worth using” are two different statements. For decades, one of the most popular agents in this category was clenbuterol, a β2-adrenergic receptor agonist developed as a bronchodilator.
Its thermogenic activity is real. So are the consequences: the literature includes cases of cardiotoxicity following clenbuterol exposure, together with a review of the issue (Barry and Graham, 2013, PMID 30546764), while more recent reports also describe poisoning in paediatric patients (Tester et al., 2020, PMID 32169984).
The conclusion is not that “older compounds were dangerous and modern ones are safe.” Thermogenic efficacy and safety are two independent dimensions, and a high value on the first says nothing about the second. The same rule applies to the compounds discussed below.
How fat burners work: four mechanisms
Instead of starting with a product list, it is more useful to identify where a compound is intended to affect energy balance. In practice, there are four main mechanisms, and the strength of the supporting evidence differs considerably between them.
Appetite suppression: the incretin axis
This is the best-documented direction, although it concerns compounds used as prescription medicines. GLP-1 receptor agonists and multi-receptor molecules act on central appetite-regulation pathways in the hypothalamus and slow gastric emptying. Drucker described the physiology of this system in detail (Drucker, 2018, PMID 29617641). The first non-peptide agonist of this class in a tablet has its own article: orforglipron.
Registration trials involving participants with obesity reported substantial changes in body weight for semaglutide (Wilding et al., 2021, PMID 33567185) and tirzepatide (Jastreboff et al., 2022, PMID 35658024). Phase 2 findings have also been published for retatrutide, a triple agonist (Jastreboff et al., 2023, PMID 37366315). The amylin analogue cagrilintide, studied in combination with semaglutide as CagriSema, has a separate article: cagrilintide.
An essential qualification: semaglutide and tirzepatide are active ingredients in prescription medicines, and all the data cited above come from trials conducted under medical supervision. Retatrutide is not approved in any jurisdiction. None of these molecules is an “over-the-counter fat burner,” and assigning therapeutic indications to research materials, for example in diabetes, falls outside the scope of this article. See the detailed comparisons of tirzepatide and semaglutide and the evidence on retatrutide.
Lipolysis and fatty-acid mobilisation
The breakdown of triglycerides in adipocytes is subject to adrenergic regulation: β receptors increase lipolysis, whereas α2 receptors inhibit it. Lipid mobilisation is therefore slower in adipose tissue with a high density of α2 receptors, which is the rationale behind α2 antagonists.
Yohimbine is an α2-adrenergic receptor antagonist. The role of these receptors in regulating lipid mobilisation from human adipose tissue was described directly (Galitzky et al., 1993, PMID 8387538), and a lipid-mobilising effect after oral administration was observed in healthy volunteers (Galitzky et al., 1988, PMID 2906290). The pharmacological profile of the molecule and its metabolites was characterised separately (Berlan et al., 1993, PMID 8097957).
The mechanism is therefore real and documented in humans, making yohimbine one of the few compounds in this category with this type of evidence. That does not make it physiologically neutral: yohimbine has a documented anxiogenic effect, described in a study of healthy participants that compared it with caffeine (Mattila et al., 1988, PMID 3153710). Its influence on neuroendocrine responses has also been studied in highly trained endurance athletes (Sommer et al., 2011, PMID 21710402). The implications of this profile are revisited in the harm-reduction section.
Thermogenesis and energy expenditure
The oldest and best-described mechanism in this group concerns caffeine. A meta-analysis covering studies of caffeine and catechin-rich teas assessed their effects on energy expenditure and fat oxidation (Hursel et al., 2011, PMID 21366839).
These results still require proportionate interpretation. Thermogenic effects of this type are measurable, but their contribution to total daily energy balance is moderate and does not replace an energy deficit. That is a more accurate conclusion than a promise to “speed up metabolism.”
Cellular metabolism and mitochondria
This is the newest and least documented group. It includes compounds that affect energy pathways inside the cell. Particular caution is needed here because the distance between a claim and the evidence supporting it is often greatest.
5-Amino-1MQ is a small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide metabolism and regulation of the NAD+ pool. Selective NNMT inhibitors were studied in a model of high-fat-diet-induced obesity in mice (Neelakantan et al., 2018, PMID 29155147), while expression of the enzyme in adipocytes was described in relation to glucose availability (Ehebauer et al., 2020, PMID 32112869). There are no human studies.
MOTS-c is a peptide encoded in the mitochondrial genome and described as a regulator of metabolic homeostasis in animal models (Lee et al., 2015, PMID 25738459). Later work described its translocation to the cell nucleus in response to metabolic stress (Kim et al., 2018, PMID 29983246). Here, too, the evidence remains preclinical. A third compound in this group, the ERR agonist called an exercise mimetic, has its own article: SLU-PP-332.
hGH Fragment 176–191 is the C-terminal segment of the growth-hormone molecule. It was isolated on the hypothesis that the lipolytic activity of hGH could be separated from its effects on growth and the IGF-1 axis. AOD-9604, an analogue of this fragment, was developed as a candidate metabolic medicine (Wilding, 2004, PMID 15134286). The programme did not result in approval. A 2026 review places molecules of this type among peptide therapies with an unconfirmed efficacy profile (Mendias and Awan, 2026, PMID 41966639).
Three claims that are not supported by the data
Several statements surrounding this category have been repeated so often that they sound like established facts. They are worth examining because each can lead to an incorrect assessment of risk.
“hGH Fragment 176–191 has no side effects”
A claim of this kind cannot be substantiated for a compound that has not completed a regulatory development pathway. An adverse-event profile is established in clinical trials of adequate size, and such trials have not been conducted for this molecule. The absence of reported adverse events when no one is systematically collecting them is not evidence of safety. Claims of “no tolerance” or “no rebound effect” are equally unsupported because they would require long-term follow-up data that do not exist.
“Modern fat burners work without side effects”
Every compound that materially affects energy metabolism has an adverse-effect profile. The only question is whether that profile has been studied. An anxiogenic effect has been documented for yohimbine (PMID 3153710). Gastrointestinal events predominate with incretin analogues, while retatrutide was additionally associated with a dose-dependent increase in heart rate (PMID 37366315). For preclinical compounds, the profile is simply unknown, which is different from having no side effects.
“SR-9009 significantly improves mitochondrial function”
This claim deserves separate treatment because a publication addressing the mechanism itself calls it into question. SR-9009, also known as stenabolic, is described as an agonist of REV-ERB, a receptor involved in circadian rhythm and metabolism. A study published in PNAS, however, found that SR9009 affected cell proliferation and metabolism even in cells lacking REV-ERB. In other words, the effects occurred independently of the receptor to which they are usually attributed (Dierickx et al., 2019, PMID 31127047).
The consequence is more important than it may first appear. If the observed activity does not occur through the declared molecular target, the mechanistic explanation behind the entire narrative about the compound requires revision, and predicting its effects and risks becomes considerably more difficult.
Harm reduction
Several practical conclusions follow directly from the mechanisms described above.
- Adrenergic stimulation is cumulative. Yohimbine increases sympathetic activity, as does caffeine. Combining several compounds with this profile adds to cardiovascular strain, and the documented anxiogenic effect of yohimbine (PMID 3153710) also applies to people without a previous history of anxiety-related difficulties.
- Individual variability is not an argument for dose titration. Advice to “find your dose” assumes that the body’s subjective response is a reliable indicator of safety. With adrenergic compounds, this is not the case: the absence of noticeable symptoms does not mean the absence of cardiovascular strain.
- Incretin analogues are active ingredients in prescription medicines. Use outside medical supervision omits the assessment of contraindications and monitoring that were integral parts of registration-trial protocols.
- Preclinical compounds do not have an established safety profile. This applies to 5-Amino-1MQ, MOTS-c, SR-9009 and hGH Fragment 176–191. A lack of data is not equivalent to data confirming an absence of risk.
- GW-501516 is a separate case. Clinical development of the compound was discontinued after tumours were observed in long-term animal toxicology studies; accelerated tumour formation was reported in a mouse model of mammary carcinogenesis (Yin et al., 2005, PMID 15867396). See the full discussion of Cardarine (GW501516).
Regulatory status and anti-doping note
The compounds discussed in this article have very different regulatory status, and in practice this distinction is more important than their division by mechanism.
| Group | Status | WADA |
|---|---|---|
| Semaglutide, tirzepatide | Active ingredients in prescription medicines | Monitoring Program; status under evaluation |
| Retatrutide | Not approved; compound under clinical investigation | S0 — non-approved substances; prohibited at all times |
| GW-501516, SR-9009 | Not approved; development of GW-501516 was discontinued | S4.4 — metabolic modulators |
| hGH Fragment 176–191 | Not approved | S2 — growth hormone and its fragments |
| Clenbuterol | Medicine outside metabolic indications | S1.2 — other anabolic agents |
| Caffeine | Food ingredient | Monitoring Program |
Substances in categories S2, S3 and S4.4 are prohibited at all times or in competition, depending on the category. Anti-doping rules are not limited to professional athletes. In Poland, the Prohibited List is implemented through the Polish Anti-Doping Agency (POLADA), and amateur competitors participating in covered events may also be tested. An athlete registered in ADAMS should verify the current Prohibited List before making any decision because the status of individual groups can change.
This guide and the current catalogue overview
Two types of material can appear similar at first glance, but they serve different purposes:
- This article is a guide to mechanisms. It explains where each group of compounds acts within energy balance and how strong the evidence is. It is evergreen content because the underlying mechanisms do not change each year.
- The fat burners category is the current catalogue overview and changes as the available research materials are updated.
If you want to understand how these mechanisms work and whether the evidence is strong, this is the appropriate guide. If you are looking for the current catalogue, use the category overview.
Frequently asked questions
Which mechanism has the strongest evidence?
The incretin axis has the strongest evidence, but this concerns active ingredients in prescription medicines studied under medical supervision. Among more widely available compounds, the best-documented mechanisms in humans are α2-receptor antagonism with yohimbine and caffeine-mediated thermogenesis. Compounds acting on cellular metabolism have only preclinical evidence.
Are there fat burners without side effects?
No. Every compound that materially affects energy metabolism has an adverse-effect profile. For some compounds it has been studied; for others it has not. The absence of a studied profile is not the same as the absence of adverse effects.
Does SR-9009 improve mitochondrial function?
The proposed mechanism is based on REV-ERB agonism. A study published in PNAS, however, found that SR9009 also produced metabolic effects in cells lacking this receptor (PMID 31127047). The compound’s actual mechanism therefore remains unclear.
Are GLP-1 analogues over-the-counter fat burners?
No. Semaglutide and tirzepatide are active ingredients in approved prescription medicines, while retatrutide is not approved in any jurisdiction. Research materials containing these molecules have a separate regulatory status and are not intended for human consumption.
Why does this article provide no doses?
Most of the compounds discussed are not medicinal products and have not passed through a regulatory process that establishes approved dosing. For preclinical compounds, such approved values do not exist.
Summary
The fat burners category includes compounds acting through four distinct mechanisms: appetite suppression through the incretin axis, lipolysis through α2-receptor antagonism, thermogenesis and interference with cellular metabolism. The strength of evidence decreases in that order, from registration trials involving thousands of participants for incretin analogues, which are nevertheless active ingredients in prescription medicines, through human volunteer data for yohimbine and caffeine, to animal and cellular models only for 5-Amino-1MQ, MOTS-c and hGH Fragment 176–191. The history of clenbuterol demonstrates that thermogenic efficacy and safety are independent dimensions. Three popular claims, concerning the absence of side effects with hGH fragments, “fat burners without adverse effects” and the mitochondrial action of SR-9009, are not supported by the literature; the last of these is challenged by a publication addressing the compound’s mechanism itself. A substantial proportion of the substances discussed also appear on the WADA Prohibited List in categories S2, S3 and S4.4.
Product documentation
Research-material pages with batch analytical documentation are available in the categories for peptides studied in lipid-metabolism models and SARMs and modulators. These materials are intended exclusively for research use.
References
- Dierickx P, Emmett MJ, Jiang C, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc Natl Acad Sci U S A. 2019;116(25):12147-12152. PMID: 31127047
- Galitzky J, Lafontan M, Nordenström J, Arner P. Role of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human adipose tissue. J Clin Invest. 1993;91(5):1997-2003. PMID: 8387538
- Galitzky J, Taouis M, Berlan M, et al. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest. 1988;18(6):587-594. PMID: 2906290
- Berlan M, Le Verge R, Galitzky J, Le Corre P. Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine. Br J Pharmacol. 1993;108(4):927-932. PMID: 8097957
- Mattila M, Seppälä T, Mattila MJ. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol. 1988;3(3):215-229. PMID: 3153710
- Sommer M, Braumann M, Althoff T, et al. Psychological and neuroendocrine responses to social stress and to the administration of the alpha-2-receptor antagonist, yohimbine, in highly trained endurance athletes. Pharmacopsychiatry. 2011;44(4):129-134. PMID: 21710402
- Hursel R, Viechtbauer W, Dulloo AG, et al. The effects of catechin rich teas and caffeine on energy expenditure and fat oxidation: a meta-analysis. Obes Rev. 2011;12(7):e573-e581. PMID: 21366839
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PMID: 29155147
- Ehebauer F, Ghavampour S, Kraus D. Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes. Life Sci. 2020;248:117474. PMID: 32112869
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
- Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. PMID: 29983246
- Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-440. PMID: 15134286
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID: 41966639
- Barry AR, Graham MM. Case report and review of clenbuterol cardiac toxicity. J Cardiol Cases. 2013;8(4):131-133. PMID: 30546764
- Tester AA, Logan S, Pollock L, McKie A. Clenbuterol: a new toxic substance in paediatrics. BMJ Case Rep. 2020;13(3):e233180. PMID: 32169984
- Yin Y, Russell RG, Dettin LE, et al. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 2005;65(9):3950-3957. PMID: 15867396
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315